Change in the Board of Managing Directors at Boehringer Ingelheim

Boehringer Ingelheim's picture
Printer-friendly versionPrinter-friendly version

Ingelheim, December 15, 2017 –  In agreement with Boehringer Ingelheim, Simone Menne,  member of the Board of Managing Directors and responsible for Corporate Board Division Finance, has decided to resign from the Board and to leave the company at the end of 2017. Ms. Menne has been a member of the Board of Managing Directors since September 1, 2016. 

Over the past year, in the course of discussions of the family-owned company’s strategy, it has become clear that it has not always been possible to reconcile divergent views and perspectives. Ms. Menne has therefore decided to leave Boehringer Ingelheim to pursue other career opportunities.

Hubertus von Baumbach, Chairman of the Board of Managing Directors, issued this statement: “Ms. Menne’s open and people-focused management style has been favorably received at every level of the organization. We greatly appreciate her contributions to the company and wish her all the best and much success in the future.”

The shareholders have chosen Michael Schmelmer to succeed her. Effective January 1, 2018, he will join the Board of Managing Directors and take over the responsibility for Corporate Board Division Finance. Since joining Boehringer Ingelheim in February 2012, Mr. Schmelmer has served as head of the company’s global IT organization. He holds degrees from the Technical University of Munich in aviation and space technology as well as industrial engineering and management. Prior to joining Boehringer Ingelheim, Mr. Schmelmer held a variety of global leadership positions at major technology companies.

Hubertus von Baumbach described this appointment as an important step in the company’s further development: “With his familiarity with a wide range of digital technologies and their applications, Mr. Schmelmer will be able to share with us the benefit of his broad knowledge, experience and ideas in a time of profound change throughout the industry.

Boehringer Ingelheim

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does. 

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: http://annualreport.boehringer-ingelheim.com.

Further Information

Our Company

Board of Managing Directors

As a family-owned company Boehringer Ingelheim is governed by the Board of Managing Directors composed of six members. Read more about their respective responsibilities.

Our Company

Get an overview of the major consolidated companies and our main business areas Human Pharmaceuticals and Animal Health

Copy this html code to your website/blog to embed this press release.

Comments

Post new comment

4 + 7 =

To prevent automated spam submissions leave this field empty.